The assessment of regiona[ ventricutar function is dependent on good endocardia[ definition. Suboptima[ images can be converted to diagnostic recordings in the majority of patients by contrast agents, which have become an indispensabte aid in rest and stress echocardiography. In particutar for stress echocardiography image quatity is essentia[ and contrast administration is of great importance. However this diagnostic procedure must be performed fottowing the indications which reflect the risks of the procedure and consider the benefits of an accurate diagnosis on further patient management. The contraindications recentty introduced in the use of the echo-contrast agent SonoVue for acute cardiac patients reflect the same contraindications which have been apptied in stress echocardiography for severa[ years. Ctinica[ triats and post-marketing surveittance have demonstrated that this approach is safe with no fatatities reported. For at[ uttrasound contrast media, side effects have been reported but they are usuatty mitd. However, rare attergic and potentiatty tile threatening reactions may occur and the investigators have to be prepared for such an event with appropriate drugs stored in the echo department. In a recent retrospective anatysis in 751 consecutive stress echocardiograms the use of contrast during dobutamine stress echocardiography was not associated with an increased risk of side effects. The incidence of side effects was very tow and different in patients receiving Optison, SonoVue or without contrast agent. Conctusion: Uttrasound contrast agents are [icensed for improvement of endocardia[ border definition. Data from ctinica[ triats and wide ctinica[ experience indicate an excettent risk/benefit ratio if the current contraindications are apptied.
Introduction
In recent years numerous ctinica[ studies have demonstrated the ctinica[ utitity of contrast echocardiography in the endocardia[ border detineation and evatuation of LV function [1] [2] [3] [4] The assessment of regiona[ ventricutar function is dependent on good endocardia[ definition. Suboptima[ images can be converted to diagnostic recordings in the majority of patients by contrast agents which have become an indispensabte aid in rest and stress echocardiography 5-7 ( Fig. 1) .
Current indications for contrast agents in Europe state that their use is targeted to "patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance [eft ventricu[ar endocardia [ border delineation"8,9 In other words contrast echocardiography represents a too[ to improve image quality. Many patients have poor images despite the advances of US technology. The use of contrast echocardiography is desirable when the anticipated image improvement may alter patient management following the evaluation of risk/benefit of procedure and possible side effects.
Improvement in patient management
Not a[[ patients in whom image quality is suboptimal need an ultrasound contrast agent to improve endocardia[ border delineation. According to the guidelines of the American Society of Echocardiography there is an indication for contrast echocardiography when the endocardial border definition in 2 or more segments is poor 1°. However, in a rest echocardiogram it is often possible to make the right clinical decisions even when the endocardial definition is poor in more than 2 segments: for instance in a 82-year-old patient with dilated LV, akinetic inferior wall and poor endocardia[ definition of the [atera[ wall further management will not be dependent on the contractility in the lateral wall (Fig. 2) .
A different situation occurs during stress echo examinations. The accuracy of stress echocardiography depends on the image quality; suboptimal images even in parts of the LV cannot be accepted. These new contraindications do not allow contrast echocardiography in patients with unstable coronary syndromes and advanced heart failure. However, they do not affect the use of SonoVue in stress echocardiography, where it is common practice to exclude unstable patients and symptomatic patients at rest. This means that the new contraindications established by EMEA are almost identical with the criteria that have been already applied for stress echo for assessing myocardial ischaemia. No significant difference was observed in the incidence of adverse events in patients with and without contrast administration. The incidence of arrhythmias or significant changes in blood pressure was very low and in concordance with data from literature on native stress echocardiography. No allergic events were seen. Recently the safety data of 1486 patients who underwent contrast dobutamine stress echocardiography with Optison have been published with similar results 16 However since side effects are very rare, we need to collect data on a wider patient population to establish the real incidence.
Comparison with other imaging technologies
Even when the risk of serious adverse events is very low, there should be a dear benefit from the application of the contrast agent to justify its use. Furthermore if there is an imaging technology for the same indication with a better risk/benefit ratio the use of contrast echocardiography could hardly be advocated. Considering the low incidence of side effects of a[[ imaging technologies it is difficult to establish a significant superiority of one method over another method concerning safety. Data from clinical trials for EMEA or FDA approval are available but do not give enough information on rare side effects 17. Post marketing surveillance, anecdotal reports on adverse events and few articles on local registries are other source to compare different technologies. However, these studies represent different populations and clinical care.
In clinical practice only myocardial scintigraphy is a real alternative for stress echocardiography if it is non diagnostic: Stress SPECT has a 0.26 SAE-rate, patients are exposed to radiation and anaphytactic SAE are also reported (<0.5% Cardiolite) 18,19. MRI may be an alternative in a few centres; it is contraindicated in patients with pacemakers and imptantabte defibrillator; in patients at early phase post-bypass surgery, gadolinium associated side effects have been reported 2°. Due to the limited stress studies performed compared to stress echocardiography or SPECT, no final judgment on risk profile is possible. Considering all the information available for the different imaging modatities there appears to be no evidence to prefer one technology for reasons of safety.
Risk/benefit considerations
For all imaging modalities the risk/benefit has to be assessed by considering the consequences of suboptimal imaging for the patient management. Assessment of risk/benefit means to compare the risks of the procedure here contrast echocardiography -with the risks of an incorrect diagnosis when not using the contrast agent. If for instance a new wall motion abnormality is not detected in stress echocardiogram because the watt is not adequately imaged, the diagnosis may be inaccurate and subsequent management of the patient may be wrong. Although it appears to be very convincing that patients with a missed diagnosis of coronary artery disease have an unfavorable outcome, there actually are only limited data to quantify to which extent this might happen. In the case of false positive studies it is easier to establish a favorable risk/benefit ratio: If a patient has a positive stress echocardiogram usually a coronary angiography is requested. This wilt expose the patient to significant radiation and the risks of the angiographic procedure including allergic or nephrotoxic reactions to the X-ray contrast agent 21. Allergic reactions and death rates associated to the procedure are 0.03-0.26% 22 exceeding the risks of echocardiographic contrast agents.
In conclusion, data from clinical trials and wide clinical experience indicate an excellent risk/benefit ratio for contrast echo and for SonoVue if the current contraindications are applied.
